We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Vertex Pharmaceuticals (VRTX - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Vertex Pharmaceuticals is a member of the Medical sector. This group includes 867 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. VRTX is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for VRTX's full-year earnings has moved 0.29% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, VRTX has moved about 7.65% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 3.57% on a year-to-date basis. This means that Vertex Pharmaceuticals is outperforming the sector as a whole this year.
Looking more specifically, VRTX belongs to the Medical - Biomedical and Genetics industry, which includes 368 individual stocks and currently sits at #71 in the Zacks Industry Rank. On average, this group has lost an average of 0.34% so far this year, meaning that VRTX is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on VRTX as it attempts to continue its solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Vertex Pharmaceuticals (VRTX - Free Report) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
Vertex Pharmaceuticals is a member of the Medical sector. This group includes 867 individual stocks and currently holds a Zacks Sector Rank of #3. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. VRTX is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for VRTX's full-year earnings has moved 0.29% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
According to our latest data, VRTX has moved about 7.65% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of 3.57% on a year-to-date basis. This means that Vertex Pharmaceuticals is outperforming the sector as a whole this year.
Looking more specifically, VRTX belongs to the Medical - Biomedical and Genetics industry, which includes 368 individual stocks and currently sits at #71 in the Zacks Industry Rank. On average, this group has lost an average of 0.34% so far this year, meaning that VRTX is performing better in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on VRTX as it attempts to continue its solid performance.